AbbVie Inc. (NYSE:ABBV) Holdings Lifted by HHM Wealth Advisors LLC

HHM Wealth Advisors LLC grew its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 9.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,257 shares of the company’s stock after buying an additional 370 shares during the period. HHM Wealth Advisors LLC’s holdings in AbbVie were worth $660,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Private Wealth Advisors LLC acquired a new stake in AbbVie in the third quarter worth approximately $201,000. Blue Fin Capital Inc. lifted its holdings in shares of AbbVie by 0.8% in the third quarter. Blue Fin Capital Inc. now owns 14,366 shares of the company’s stock valued at $2,141,000 after buying an additional 111 shares during the period. WestEnd Advisors LLC boosted its stake in AbbVie by 29.9% during the third quarter. WestEnd Advisors LLC now owns 128,176 shares of the company’s stock valued at $19,106,000 after buying an additional 29,506 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in AbbVie by 1.6% during the third quarter. Aaron Wealth Advisors LLC now owns 26,870 shares of the company’s stock worth $4,005,000 after acquiring an additional 411 shares during the period. Finally, Consolidated Investment Group LLC raised its position in AbbVie by 32.7% in the third quarter. Consolidated Investment Group LLC now owns 14,600 shares of the company’s stock worth $2,176,000 after acquiring an additional 3,600 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ABBV. Guggenheim lifted their price target on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. William Blair upgraded AbbVie from a “market perform” rating to an “outperform” rating in a report on Monday, January 29th. Barclays upped their target price on AbbVie from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, March 27th. Raymond James lifted their price target on AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Finally, BMO Capital Markets upped their price objective on shares of AbbVie from $187.00 to $195.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and an average target price of $177.43.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 5,144 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $176.65, for a total transaction of $908,687.60. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,233,546.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Azita Saleki-Gerhardt sold 52,870 shares of the firm’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $173.71, for a total value of $9,184,047.70. Following the completion of the transaction, the executive vice president now directly owns 243,944 shares of the company’s stock, valued at $42,375,512.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Kevin K. Buckbee sold 5,144 shares of the business’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $176.65, for a total transaction of $908,687.60. Following the completion of the sale, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,233,546.95. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 383,324 shares of company stock worth $67,780,003. Insiders own 0.25% of the company’s stock.

AbbVie Stock Down 4.6 %

Shares of NYSE:ABBV traded down $7.67 on Friday, reaching $159.62. The company had a trading volume of 10,721,740 shares, compared to its average volume of 5,004,945. The stock has a market capitalization of $282.63 billion, a P/E ratio of 47.37, a P/E/G ratio of 2.03 and a beta of 0.58. The stock has a 50-day moving average price of $174.59 and a 200 day moving average price of $160.82. AbbVie Inc. has a twelve month low of $130.96 and a twelve month high of $182.89. The company has a quick ratio of 0.76, a current ratio of 0.87 and a debt-to-equity ratio of 5.02.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, April 26th. The company reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.26 by $0.05. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. The company had revenue of $12.31 billion for the quarter, compared to analyst estimates of $11.93 billion. During the same quarter last year, the firm posted $2.46 earnings per share. The company’s quarterly revenue was up .7% compared to the same quarter last year. On average, equities analysts expect that AbbVie Inc. will post 11.19 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be paid a $1.55 dividend. The ex-dividend date of this dividend is Friday, April 12th. This represents a $6.20 annualized dividend and a dividend yield of 3.88%. AbbVie’s payout ratio is 183.98%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.